Orexigen Therapeutics, Inc. (NASDAQ:OREX) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.13) by $0.78, Briefing.com reports. Orexigen Therapeutics had a negative net margin of 192.65% and a negative return on equity of 6,557.16%. The firm had revenue of $18.90 million during the quarter, compared to analyst estimates of $24.20 million. During the same quarter in the prior year, the business posted $1.12 earnings per share. The company’s quarterly revenue was up 170.0% compared to the same quarter last year.
Shares of Orexigen Therapeutics (OREX) opened at $1.71 on Wednesday. The company has a debt-to-equity ratio of -4.08, a current ratio of 2.74 and a quick ratio of 2.36. Orexigen Therapeutics has a 52 week low of $1.58 and a 52 week high of $5.70.
Several research firms recently issued reports on OREX. ValuEngine lowered shares of Orexigen Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Zacks Investment Research raised shares of Orexigen Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research report on Monday, August 14th.
TRADEMARK VIOLATION WARNING: This report was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://sportsperspectives.com/2017/11/15/orexigen-therapeutics-inc-orex-issues-quarterly-earnings-results-beats-estimates-by-0-78-eps.html.
Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
Receive News & Ratings for Orexigen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.